Literature DB >> 18568956

Early effects of treatment with nebivolol and quinapril on endothelial function in patients with hypertension.

Hasan Korkmaz1, Ilgin Karaca, Mustafa Koç, Orhan Onalan, Mücahit Yilmaz, Mehmet Nail Bilen.   

Abstract

The objective of the present study was to compare the early effects of treatment with nebivolol and quinapril on the endothelial function in hypertensive patients. A total of 54 hypertensive patients was enrolled in the present study. One of the groups (n = 27) received quinapril 20 mg/day, and the other group (n = 27) received nebivolol 5 mg/day for a period of 4 weeks. The endothelial dysfunction was assessed using FMD (flow-mediated vasodilation) of the brachial arteries. The baseline characteristics of both groups were similar in age, gender, left venticular ejection fraction, left ventricular mass index, and body mass index. No significant difference was also found between the groups in the distribution of atherosclerotic risk factors as well as other echocardiographic, demographic, and biochemical measurements. Although the reduction of diastolic blood pressure was more pronounced in the nebivolol group after a 4-week treatment, the change in the systolic blood pressure was found to be similar in both treatment arms. Although a statistically nonsignificant increase was observed in flow-mediated vasodilation in the quinapril group (4.77% +/- 3.92%, 5.60% +/- 6.18%; p = .587), the increase in the post-treatment FMD was statistically significant in the nebivolol group (3.78% +/- 4.25%, 8.56% +/- 6.39%; p = .002). A significant change was observed in the resistive index value following flow-mediated vasodilation for both groups after treatment (p = .043; p = .027), whereas the change in the value of flow volume was significant only in the nebivolol group (p = .019).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18568956     DOI: 10.1080/10623320802125565

Source DB:  PubMed          Journal:  Endothelium        ISSN: 1026-793X


  5 in total

1.  Does brachial artery flow-mediated vasodilation provide a bioassay for NO?

Authors:  D Walter Wray; Melissa A H Witman; Stephen J Ives; John McDaniel; Joel D Trinity; Jamie D Conklin; Mark A Supiano; Russell S Richardson
Journal:  Hypertension       Date:  2013-06-17       Impact factor: 10.190

2.  The effect of antihypertensive drugs on endothelial function as assessed by flow-mediated vasodilation in hypertensive patients.

Authors:  Michiaki Miyamoto; Kazuhiko Kotani; Shun Ishibashi; Nobuyuki Taniguchi
Journal:  Int J Vasc Med       Date:  2012-02-29

Review 3.  Comparative Efficacy of Antihypertensive Agents in Flow-Mediated Vasodilation of Patients with Hypertension: Network Meta-Analysis of Randomized Controlled Trial.

Authors:  Hong Ding; Shu Liu; Ke-Xin Zhao; Jie Pu; Ya-Fei Xie; Xiao-Wei Zhang
Journal:  Int J Hypertens       Date:  2022-04-30       Impact factor: 2.434

4.  Nebivolol in obese and non-obese hypertensive patients.

Authors:  Camila Manrique; Adam Whaley-Connell; James R Sowers
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-06       Impact factor: 3.738

5.  Carvedilol-lisinopril combination therapy and endothelial function in obese individuals with hypertension.

Authors:  Aaron S Kelly; J Michael Gonzalez-Campoy; Kyle D Rudser; Harold Katz; Andrea M Metzig; Melissa Thalin; Alan J Bank
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-12-19       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.